SBC Medical Group Holdings Inc 8-K

What Happened
SBC Medical Group Holdings Inc. filed an 8‑K reporting that, at its July 8, 2026 annual meeting, shareholders approved a Restated Certificate of Incorporation and the board adopted Amended and Restated Bylaws. The Restated Charter was filed with the Delaware Secretary of State and became effective on July 9, 2026. Separately, the company notified Nasdaq that, due to director Mike Sayama’s decision not to seek re‑election, it no longer meets Nasdaq’s independence requirements for the board and the audit committee; Nasdaq confirmed noncompliance in a July 10, 2026 notice but granted a cure period.

Key Details

• Restated Charter effective July 9, 2026; key charter changes approved include: eliminating plurality voting for directors, removing the “only for cause” removal restriction, opting out of DGCL Section 203, adding officer exculpation, and other technical changes.
• Amended and Restated Bylaws adopted July 8, 2026; updates include majority‑voting/quorum rules, universal proxy rules (Rule 14a‑19) incorporation, enhanced advance notice and nomination disclosures, meeting procedures, and other clarifications.
• Director change: Mike Sayama did not seek re‑election at the July 8, 2026 meeting; after his departure the board has 4 members, only 2 of whom qualify as independent under Nasdaq rules. The audit committee has two independent members but requires three.
• Nasdaq cure period: the company has until the earlier of its next annual meeting or July 9, 2027 to restore compliance (or, if the next annual meeting occurs before Jan 5, 2027, then no later than Jan 5, 2027). The board is searching for a fifth independent director to join and serve on the audit and other committees.

Why It Matters
These filings change shareholder governance rights (e.g., majority voting, director removal standards, and opt‑out of DGCL 203) and update meeting and nomination procedures, which can affect how shareholders nominate directors and how control contests proceed. The Nasdaq notice is material because failure to restore the required number of independent directors and audit committee members by the cure deadline could lead to further Nasdaq action; for now the company remains listed while it seeks an independent director to regain compliance. Investors should note the governance changes and monitor follow‑up filings about director additions and any Nasdaq correspondence.